Skip to Content

Frequently Searched

Supported by

Clinical White Papers: Insight & Practical Application

NCODA’s clinical white papers are evidence-informed resources developed by expert oncology professionals to support high-quality, patient-centered care. Focused on real-world challenges and best practices, these papers provide practical guidance on treatment approaches, symptom management, workflow optimization, and more. Designed to support the entire oncology care team, NCODA white papers help translate clinical knowledge into actionable strategies that enhance outcomes and improve the patient experience.

Clinical Papers

SORT

Operationalizing Outpatient Bispecific Therapy: Practical Considerations for Safe and Sustainable Implementation

October 6, 2026
58% of surveyed oncology professionals report delivering bispecific step-up dosing in the outpatient setting. But what does it take to do it safely? In a new NCODA white paper, Tara Graff, DO, MS, explores insights from 126 oncology professionals on the real-world challenges and practical considerations for implementing outpatient bispecific T-cell engager (BTCE) programs.

PEComa Care Delivery Across the Academic–Community Oncology Continuum

January 13, 2026
Perivascular epithelioid cell tumors (PEComas) are ultra-rare mesenchymal malignancies that present significant diagnostic and treatment challenges across oncology settings. This white paper examines PEComa care delivery across the academic–community oncology continuum, using real-world perspectives from both settings to illustrate how diagnosis, treatment, and long-term management are operationalized in practice.

Provider Perspectives on Clinical and Non-Clinical Considerations in BTKi Selection

December 18, 2025
Bruton tyrosine kinase inhibitors (BTKis) have become foundational therapies in the management of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). As treatment options have expanded beyond first-generation agents, oncology providers are increasingly navigating a complex decision-making landscape that extends beyond clinical trial data alone.

Prostate Cancer: Imaging and Therapy Options from an Oncology Perspective

October 17, 2025
This clinical review outlines the latest advances in imaging and radiopharmaceutical therapy for prostate cancer, including PSMA-targeted diagnostics and treatments such as Pluvicto® and Xofigo®. It highlights evolving FDA approvals, therapy sequencing, and practical adoption strategies to help oncology practices integrate these innovations effectively into patient care.

Low-Dose Abiraterone with a Low-fat Diet in Metastatic Prostate Cancer

October 15, 2025
This case series from the Fred Hutchinson Cancer Center explores the use of low-dose abiraterone taken with a low-fat meal as a cost-effective alternative to standard dosing for metastatic prostate cancer. Results showed comparable efficacy and safety, with significant cost savings and manageable side effects, underscoring the importance of consistent dietary education for patients. The findings support further prospective studies to validate this dosing strategy.

Universal DPYD Testing Prior to 5-FU and Capecitabine Therapy 

October 6, 2025
This white paper outlines the clinical, economic, and policy rationale for universal DPYD testing prior to 5-FU and capecitabine therapy. Evidence shows that genotype-guided dosing prevents severe toxicities, reduces hospitalizations and healthcare costs, and aligns U.S. oncology practice with international safety standards. The authors recommend implementing universal DPYD testing as a precision medicine strategy to improve patient safety and value-based cancer care.